Senescent Cells & Senolytics

What is cellular senescence?

Cellular senescence is a state where a cell permanently stops dividing in response to stress — DNA damage, telomere shortening, oncogene activation, or oxidative stress — but crucially does not die. The cell enters a stable growth arrest mediated primarily by the p53/p21 and p16INK4a/Rb tumor suppressor pathways.

Senescence evolved as an anti-cancer mechanism: a damaged cell that might otherwise become malignant is forced into permanent growth arrest. In young organisms, senescent cells are efficiently cleared by the immune system (primarily NK cells and macrophages). The problem emerges with aging — immune surveillance declines, and senescent cells accumulate in tissues faster than they are cleared.

The SASP: why accumulation matters

Senescent cells are not inert. They secrete a complex mixture of pro-inflammatory cytokines (IL-6, IL-8, IL-1β), matrix metalloproteinases, growth factors, and chemokines collectively termed the senescence-associated secretory phenotype (SASP). The SASP:

• Drives chronic low-grade inflammation (inflammaging) — a recognized hallmark of aging
• Degrades the extracellular matrix via MMP secretion — contributing to tissue stiffness and architectural decline
• Induces senescence in neighboring healthy cells (paracrine senescence) — creating a positive feedback loop
• Promotes fibrosis — aberrant wound healing in tissues ranging from liver to lung to kidney
• Paradoxically promotes cancer — the same mechanism that stops one cell from dividing creates a pro-tumorigenic microenvironment for neighboring cells

The burden of senescent cells increases exponentially with age and correlates with age-related diseases: osteoarthritis, atherosclerosis, pulmonary fibrosis, renal decline, sarcopenia, and neurodegeneration.

How senescent cells resist death

Normal cells with irreparable damage undergo apoptosis (programmed cell death). Senescent cells evade apoptosis through upregulation of anti-apoptotic pathways — the BCL-2 family of survival proteins, the FOXO4-p53 interaction (in which FOXO4 sequesters p53 away from apoptotic gene targets), and PI3K/AKT survival signaling.

This resistance to death is the therapeutic target for senolytics.

Senolytics: clearing the burden

Senolytics are compounds that selectively induce apoptosis in senescent cells while sparing healthy cells. The selectivity is based on the pro-survival pathways that senescent cells depend on — disrupting these pathways triggers death specifically in cells that rely on them.

Small-molecule senolytics

• Dasatinib + Quercetin (D+Q): The most studied senolytic combination. Dasatinib (a tyrosine kinase inhibitor) targets senescent preadipocytes; quercetin (a flavonoid) targets senescent endothelial cells. Intermittent dosing in humans has shown reduced senescent cell markers and improved physical function in pilot studies (idiopathic pulmonary fibrosis, diabetic kidney disease).
• Navitoclax (ABT-263): A BCL-2 family inhibitor that disrupts the anti-apoptotic proteins senescent cells rely on. Effective but limited by thrombocytopenia (platelet toxicity) because BCL-XL is essential for platelet survival.
• Fisetin: A natural flavonoid with senolytic activity in preclinical models. Human trials are ongoing (AFFIRM trial).

Peptide senolytics

• FOXO4-DRI: A D-retro-inverso peptide designed to disrupt the FOXO4-p53 interaction specifically. In senescent cells, FOXO4 physically binds p53 in PML nuclear bodies, preventing p53 from activating apoptotic genes. FOXO4-DRI competes for this binding site, releasing p53 to trigger apoptosis. The selectivity arises because non-senescent cells lack the FOXO4-p53 complex. De Keizer et al. (2017) demonstrated rejuvenation effects in naturally aged mice. This is the only published peptide senolytic with in vivo proof of concept.

Key concepts for the peptide user

• Intermittent dosing is essential. Senolytics are "hit-and-run" drugs — they are administered in brief pulses to clear accumulated senescent cells, then discontinued. Continuous exposure increases off-target risk without additional benefit, because senescent cells accumulate slowly.
• Immune clearance follows drug exposure. After a senolytic pulse kills senescent cells, the immune system must clear the apoptotic debris. Adequate immune function and recovery time between pulses is important.
• Not all senescent cells are bad. Transient senescence plays roles in wound healing, embryonic development, and tumor suppression. Senolytics should target the chronically accumulated burden, not interfere with acute senescence during healing.
• Biomarkers are maturing. p16INK4a expression, SASP cytokine panels, and senescence-associated beta-galactosidase (SA-β-gal) staining are research tools. Clinical-grade senescent cell quantification is still evolving.

Current evidence status

Cellular senescence as a driver of aging is well-established (one of the nine hallmarks of aging proposed by López-Otín et al., 2013). Small-molecule senolytics have entered human clinical trials with early positive signals. Peptide senolytics (FOXO4-DRI) remain at the preclinical stage. The field is progressing rapidly, but clinical validation of peptide-based senolytic strategies is still pending.